Low Non-Inferiority Margin Meant Smooth Sailing For Vibativ Efficacy Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Low Non-Inferiority Margin Meant Smooth Sailing For Vibativ Efficacy Review
You may also be interested in...
Industry’s Lesson On Non-Inferiority Margins In Anti-Infective Trials: Use 10%
If industry is to learn anything from the three-day Anti-Infective Drugs Advisory Committee meeting on how to correctly use non-inferiority margins in trials, it is to adhere to the panel's recommendation of 10 percent (at least for now)
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product